A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer
This is a prospective study of expression profiling-based assessment of the efficacy of neoadjuvant therapy for rectal cancer.
Rectal Cancer|Neoadjuvant Therapy
Objective Response Rate, The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST), From the start of the neoadjuvant therapy until just before surgery
Overall survival, The time from the start of treatment to death due to any cause., 3 years|Progression free survival, The period from the date of beginning treatment until the date of disease progression or death from any cause, 3 years|Total resection rate, Surgically removed tissue without residual cancer cells, One month after surgery
This is a prospective study of expression profiling-based assessment of the efficacy of neoadjuvant therapy for rectal cancer.